Amyloid Causes Alzheimer's Disease

False Assumption: Amyloid proteins are the primary cause of Alzheimer's disease, prompting a cascade of biochemical changes that lead to dementia.

Summaries Written by FARAgent (AI) on February 10, 2026 · Pending Verification

For more than 30 years, the governing idea in Alzheimer’s research was the amyloid cascade hypothesis: amyloid-beta builds up first, then tau, inflammation, synapse loss, and finally dementia. That view did not come from nowhere. Researchers had isolated amyloid from plaques, cloned the amyloid precursor protein gene, and found rare inherited mutations that increased amyloid production in families with early onset Alzheimer’s. Brain tissue was full of plaques, and the field had a clean, testable story, one many reasonable scientists took as the best available map of the disease.

By the 2000s and 2010s, that map had become doctrine. Drug programs, grant funding, and review articles treated amyloid lowering as the obvious route to treatment, even after one clinical failure after another. The trouble was plain enough: many patients with heavy plaque burden did not track neatly with dementia, and clearing amyloid often failed to produce meaningful cognitive benefit. Then came deeper embarrassment. Investigations by Charles Piller and others raised serious questions about manipulated images and unreliable findings in influential papers, including work long used to support the field’s confidence. Retractions followed, but only after years of resistance.

The debate now is not whether amyloid matters at all, but whether it deserved to sit at the center of the whole enterprise. A substantial body of experts now rejects the strong claim that amyloid is the primary driver in most Alzheimer’s disease, pointing to repeated trial failures, weak clinical effects from anti-amyloid drugs, and real risks such as brain swelling, bleeding, and faster brain shrinkage. Others still argue amyloid remains upstream, especially in early or genetic cases, and cite newer studies linking soluble amyloid species to later decline. So the old slogan, “remove the amyloid, stop the disease,” has not survived intact. What remains is a narrower, less triumphant version of the theory.

Status: A significant portion of experts think this assumption was false

People Involved

Marc Tessier-Lavigne served as a senior author on the 2009 Nature paper and later became president of Stanford University while maintaining a reputation as a leader in Alzheimer's brain circuitry research. He promoted the paper's claims about DR6 and N-APP binding as a breakthrough that could turn understanding of the disease upside down, citing it in NIH grant applications even after internal reproducibility failures surfaced in 2012. Stanford eventually investigated his labs and confirmed multiple instances where he failed to correct the scientific record despite evidence of image anomalies and inconsistent results. He resigned the presidency in 2023 after the pattern became public. The episode illustrated how institutional prestige could shield questionable work for more than a decade. ^[5][15]
Sylvain Lesné was the first author of the influential 2006 Nature paper that claimed to isolate the Aβ*56 oligomer from transgenic mice and showed it caused memory impairment when injected into rats. The work became one of the most cited pieces of evidence for the amyloid hypothesis and shaped research priorities for years. A 2021 investigation by Matthew Schrag identified dozens of apparently manipulated images across Lesné's papers, including duplicated and composite figures that had supported the oligomer's role. Elisabeth Bik reviewed the dossier and described some alterations as shockingly blatant. The University of Minnesota, where Lesné worked, began reviewing the concerns. ^[6]
Dennis J Selkoe and John Hardy co-authored a 2016 review in EMBO Molecular Medicine that defended the amyloid hypothesis as the dominant model after 25 years, citing genetic mutations in APP and presenilins as proof that Aβ dyshomeostasis initiates the disease. Both men occupied influential academic posts, Selkoe at Harvard Medical School and Hardy at the UCL Institute of Neurology, and their writings helped maintain the framework in textbooks, grant proposals, and clinical trial design. They acknowledged some inconsistencies but argued the genetic evidence remained compelling. Their continued advocacy illustrated how senior figures could sustain the assumption even as clinical results disappointed. ^[4]
Eliezer Masliah produced roughly 800 papers as first or last author while rising to direct the National Institute on Aging's $2.6 billion Division of Neuroscience. His Western blots and micrographs appeared in high-impact journals and influenced both basic science and drug development pipelines, including trials of prasinezumab for Parkinson's. A 300-page dossier assembled by Matthew Schrag and forensic analysts documented falsified images reused across papers with contradictory experimental conditions. The NIH later found research misconduct in two of his publications. Eleven neuroscientists who reviewed the dossier concluded that most anomalies could not be dismissed as honest error. ^[7]

▶ Supporting Quotes (41)

“Mr. Piller is an investigative journalist for Science. This essay is adapted from his upcoming book, “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s.””— Beyond the Alzheimer's Research Fraud

“R Matthew Hutchison a Biogen, Inc, 225 Binney Street, Cambridge, MA, 02142, USA ⁎ Corresponding author at: Biogen, Inc, 225 Binney Street, Cambridge, MA 02142 USA. [email protected]”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Tianle Chen a Biogen, Inc, 225 Binney Street, Cambridge, MA, 02142, USA”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“The amyloid (or Aβ) hypothesis (Beyreuther & Masters, 1991; Hardy & Allsop, 1991; Selkoe, 1991; Hardy & Higgins, 1992) has become the dominant model of AD pathogenesis and is guiding the development of potential treatments.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“the idea put forward by George Glenner (Glenner & Wong, 1984) that the particular amyloidogenic protein accumulating in AD (Aβ) could be causative”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Dr. Tessier-Lavigne, the paper’s senior author, was an Executive Vice President of the Genentech Research organization.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“The 2009 Nature paper was co-authored by former Genentech researchers Drs. Anatoly Nikolaev and Marc Tessier-Lavigne”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“The first author of that influential study, published in Nature in 2006, was an ascending neuroscientist: Sylvain Lesné of the University of Minnesota (UMN), Twin Cities.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“Ashe touted Aβ*56 on her website as “the first substance ever identified in brain tissue in Alzheimer’s research that has been shown to cause memory impairment.””— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“In August 2021, Matthew Schrag, a neuroscientist and physician at Vanderbilt University, got a call... Schrag’s sleuthing drew him into a different episode of possible misconduct, leading to findings that threaten one of the most cited Alzheimer’s studies of this century”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“The authors “appeared to have composed figures by piecing together parts of photos from different experiments,” says Elisabeth Bik, a molecular biologist and well-known forensic image consultant.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

““MASLIAH IS THE SOLE common author on every paper in the dossier, usually taking the first or last position in multiauthor articles. Those positions imply he did the majority of the publication’s work or bears primary responsibility for it, although the others contributed.” “Given the extended time frame and huge number of differing collaborators and co-authors on these papers, [possible misconduct] by a rogue postdoc or a collaborating scientist doesn’t apply here,” says Tim Greenamyre”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

““The volume of papers and resources involved are enormous—as is Dr. Masliah’s leadership and influence on the field, including drug development pipelines,” says Vanderbilt University neuroscientist Matthew Schrag, one of those who helped assemble the dossier.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

““I’m floored,” says Samuel Gandy, a prominent neurologist at the Mount Sinai Alzheimer’s Disease Research Center who was visibly shaken during a video interview. “Hundreds of images. There had to have been ongoing manipulation for years.””— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“✉ Correspondence, Zung Vu Tran, Biomed Industries, Inc., San Jose, CA, USA. Email: [email protected] ✉ Corresponding author.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Lloyd Tran 1 Biomed Industries, Inc., San Jose, CA, USA”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Dennis J Selkoe 1 Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA ... John Hardy 2 Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK”— The amyloid hypothesis of Alzheimer's disease at 25 years

“the idea put forward by George Glenner (Glenner & Wong, 1984) that the particular amyloidogenic protein accumulating in AD (Aβ) could be causative has met with considerable skepticism”— The amyloid hypothesis of Alzheimer's disease at 25 years

““Beta amyloid appears to directly affect the hippocampus, a key region for memory, so acting early could significantly reduce the risks associated with Alzheimer's,” says Dr. Raffaele Cacciaglia, BBRC researcher and leader of the study.”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“Marc Tessier-Lavigne, the former president of Stanford University, was known as a global leader in research on the brain’s circuitry in Alzheimer’s and other neurological conditions. He resigned in 2023 after an intrepid student journalist revealed numerous altered images in his research. Dr. Tessier-Lavigne didn’t personally falsify data or coerce junior colleagues to do so. But he failed to correct dubious results that came to his attention”— Beyond the Alzheimer's Research Fraud

“GLENNER, G.G., ALZHEIMERS-DISEASE - INITIAL REPORT OF THE PURIFICATION AND CHARACTERIZATION OF A NOVEL CEREBROVASCULAR AMYLOID PROTEIN, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 120: 885 (1984).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“GLENNER, G.G., ALZHEIMERS-DISEASE AND DOWNS-SYNDROME - SHARING OF A UNIQUE CEREBROVASCULAR AMYLOID FIBRIL PROTEIN, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 122: 1131 (1984).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“CHARTIERHARLIN, M.C., EARLY-ONSET ALZHEIMERS-DISEASE CAUSED BY MUTATIONS AT CODON-717 OF THE BETA-AMYLOID PRECURSOR PROTEIN GENE, NATURE 353: 844 (1991).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“GOATE, A, SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE, NATURE 349: 704 (1991).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“GOLDGABER, D, CHARACTERIZATION AND CHROMOSOMAL LOCALIZATION OF A CDNA-ENCODING BRAIN AMYLOID OF ALZHEIMERS-DISEASE, SCIENCE 235: 877 (1987).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“”While there may be many causes of Alzheimer’s disease (AD), the same pathological sequence of events […] is likely to occur in all cases. […] The pathological cascade for the disease process is likely to be beta-amyloid deposition—tau phosphorylation and tangle formation—neuronal death. The development of biochemical understanding of this pathological cascade will facilitate the rational design of drugs to intervene in this process.” Thus wrote John Hardy and David Allsop in 1991”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Marc Tessier-Lavigne told shareholders in 2009 that his research would “turn our current understanding of Alzheimer’s upside down.””— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“He continued to cite the paper in grant applications, according to National Institutes of Health filings reviewed by The Daily.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“When Prusiner and Master's interest in these plaques began, others showed they consisted of a novel amyloid fibril containing highly aggregating small polypeptides about 40 amino acids long with a molecular mass of 4kDa, now known as amyloid-beta (Aβ).”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“The first author of that influential study, published in Nature in 2006, was an ascending neuroscientist: Sylvain Lesné of the University of Minnesota (UMN), Twin Cities. His work underpins a key element of the dominant yet controversial amyloid hypothesis of Alzheimer’s”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“It emerged from the lab of UMN physician and neuroscientist Karen Ashe, who had already made a remarkable series of discoveries. ... Ashe touted Aβ*56 on her website as “the first substance ever identified in brain tissue in Alzheimer’s research that has been shown to cause memory impairment.””— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“This led to the amyloid cascade hypothesis proposed in a seminal paper by John Hardy and Gerrald Higgins (1992). They posited that beta-amyloid was the causative agent of AD, and that other changes, such as the accumulation of tau protein neurofibrillary tangles, were downstream consequences.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“Among researchers convinced that pursuing AADS is a promising direction is Christian Haass, Head of the Laboratory of Neurodegenerative Disease Research at Ludwig–Maximilians University in Munich, Germany. He considers recent results have delivered final proof of the amyloid cascade hypothesis.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“Bart De Strooper, a Belgian molecular biologist at the University College London, as well as founding director of the UK Dementia Research Institute. “There is no other drug for AD, and AD is a terrible disease. I believe that patients and doctors should at least have the choice to decide whether they want to give it a try or not."”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“In notes taken during a voyage to South America on the HMS Beagle in the 1830s, Charles Darwin described an illness that he believed was caused by "miasma" emanating from stagnant pools of water.”— Definition of MIASMA

“Statement of Dr. Beverly Winikoff,’Rockefeller Foundation’’New York”— Dietary Goals for the United States, Second Edition

“Lee, professor of social medicine’and’director’ Pro^rarn» University of California, San Francisco, Calif__”— Dietary Goals for the United States, Second Edition

“In his book, Piller, an investigative reporter at Science magazine, presents copious evidence of severe fraud, negligence, and buck-passing in Alzheimer’s research.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“One notable exception is Elisabeth Bik, a Dutch microbiologist and legendary image sleuth who has taken on Alzheimer’s fraud.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“Writing in his column for i, my buddy Stuart Ritchie has a good take on the new Alzheimer’s drug donanemab”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

Organizations Involved

Genentech published the 2009 Nature paper from its own researchers and featured the work in its annual shareholder letter and investor presentations to Roche. Executives used the findings to help justify raising the acquisition price by roughly four billion dollars. The company launched a multi-year drug discovery program targeting the DR6 pathway and maintained internal weekly reviews supporting it until 2012, when its own scientists could no longer reproduce the core binding results. Genentech eventually ceased the Alzheimer's program after the biology proved unreliable. The episode showed how corporate resources could be mobilized behind a single high-profile claim. ^[5][15]

National Institutes of Health provided tens of millions in funding for Sylvain Lesné's work and continues to allocate about 1.6 billion dollars annually, roughly half its Alzheimer's budget, to amyloid-related projects. The agency appointed Eliezer Masliah to head the National Institute on Aging's neuroscience division, giving him influence over grant priorities and drug development pipelines. After a Science investigation and a 300-page dossier, the NIH found research misconduct in two of Masliah's publications but offered no comprehensive statement on broader implications. The funding pattern demonstrated how institutional inertia can keep resources flowing toward a contested framework. ^[6][7]

Biogen employed several authors of a review that positioned amyloid-beta reduction as a surrogate endpoint likely to predict clinical benefit in Alzheimer's trials. The company ran clinical development programs for anti-amyloid antibodies and supplied statistical evidence that helped sustain regulatory interest in the approach. Its work contributed to the approval of aducanumab under the FDA's accelerated pathway despite modest cognitive results. Biogen's institutional weight helped keep the amyloid model embedded in late-stage drug development even after many earlier failures. ^[3]

University of Minnesota employed both Sylvain Lesné and senior author Karen Ashe, whose lab produced the 2006 Nature paper that became a cornerstone of the amyloid hypothesis. The institution is now reviewing complaints about image manipulation in Lesné's body of work. Its earlier support for the research helped embed the Aβ*56 oligomer in the scientific literature for 15 years before serious questions arose. The university's role illustrated how academic homes can amplify influential but later-disputed findings. ^[6]

▶ Supporting Quotes (32)

“Nearly every drug approved for Alzheimer’s dementia symptoms is based on it, despite producing meager results. The anti-amyloid antibody drugs approved in the United States cost tens of thousands of dollars per patient per year”— Beyond the Alzheimer's Research Fraud

“according to an investigation by a special committee appointed by the university’s board of trustees.”— Beyond the Alzheimer's Research Fraud

“a Biogen, Inc, 225 Binney Street, Cambridge, MA, 02142, USA”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Paul Aisen g Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of University of Southern California”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK”— The amyloid hypothesis of Alzheimer's disease at 25 years

“The early-stage research program evolved into a DR6 drug discovery program in 2009 and that program continued until it was ultimately terminated in 2012.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“a 2009 scientific paper published in the journal Nature (Nature. 2009 Feb 19;457(7232):981-9).”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“NIH spent about $1.6 billion on projects that mention amyloids in this fiscal year, about half its overall Alzheimer’s funding.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“A UMN spokesperson says the university is reviewing complaints about his work.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“He took the helm at the agency’s Division of Neuroscience, whose budget—$2.6 billion in the last fiscal year—dwarfs the rest of NIA combined. As a leading federal ambassador to the research community and a chief adviser to NIA Director Richard Hodes, Masliah would gain tremendous influence”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“today, the National Institutes of Health (NIH) released a statement saying that following an investigation, it had “made findings of research misconduct” against Masliah for “falsification and/or fabrication involving re-use and relabel of figure panels” in two publications.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“The physician and neuropathologist conducted research at the University of California San Diego (UCSD) for decades... UCSD. The university declined to comment”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Reta Lila Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK”— The amyloid hypothesis of Alzheimer's disease at 25 years

“A study by the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, has identified that the accumulation of beta amyloid can, on its own, cause brain damage in the early stages of Alzheimer's”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“360 middle-aged volunteers without cognitive impairment from the Alfa cohort, promoted by ”la Caixa” Foundation.”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“according to an investigation by a special committee appointed by the university’s board of trustees.”— Beyond the Alzheimer's Research Fraud

“Within a year, Athena Neurosciences, where Games worked, was acquired by Elan Corp. for a staggering $638 million. In the press release announcing the merger, Elan proclaimed that the acquisition “provides the opportunity for us to capitalize on an important therapeutic niche, by combining Athena’s leading Alzheimer’s disease research program with Elan’s established development expertise.””— The Internet You Missed: A 2025 Snapshot

“In 2020, the National Institute of Aging supported AD research and clinical trial studies with $2.8 billion”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

““Prior to publication of the paper, employees other than the authors performed binding experiments that showed inconsistent results,” Genentech said in an April statement. “Senior leaders at Genentech including Dr. Tessier-Lavigne knew of the inconsistent binding results,””— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“He resigned as president this summer after a Stanford-sponsored investigation confirmed a pattern of falsified research emerging from labs he ran.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“Schrag sent all of them to the National Institutes of Health (NIH), which had invested tens of millions of dollars in the work. ... NIH spent about $1.6 billion on projects that mention amyloids in this fiscal year, about half its overall Alzheimer’s funding.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“Early this year, Schrag raised his doubts with NIH and journals including Nature; two, including Nature last week, have published expressions of concern about papers by Lesné.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“The approval of lecanemab mirrors the fate of the first AAD called aducanumab, marketed as Aduhelm by Biogen, which acquired the exclusive rights from the Swiss biotech firm Neurimmune. Aducanumab was similarly refused marketing authorization by the EMA in 2022 after it had been approved by the FDA.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“The recent rejection of lecanemab by the European Medicines Agency (EMA) in July 2024—after approval by the US Food and Drug Administration (FDA) a year earlier.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“Keys was professor and director of the Laboratory of Physiological Hygiene at the University of Minnesota, School of Public Health between 1940 and 1972.”— Ancel Keys

“From fabricated images published in major research journals (many of them still unretracted) ... journals have frequently slow-walked subsequent investigations and have proven quite reluctant to retract papers that seem to plainly warrant it”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“universities have frequently closed ranks around researchers credibly suspected of fraud rather than engage in prompt and thorough investigations.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“to the complete negligence of federal watchdogs”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“a new study just published in JAMA”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

The Foundation

The amyloid hypothesis held that amyloid proteins prompt a cascade of biochemical changes that lead to dementia. A thoughtful observer in the 1990s would have found the idea persuasive because mutations in the amyloid precursor protein gene and in presenilin genes, which alter Aβ production, reliably caused early-onset familial Alzheimer's disease. Geneticists had shown that these mutations increased the Aβ42 to Aβ40 ratio and that people with Down syndrome, who carry an extra copy of the APP gene, developed amyloid deposits followed by full Alzheimer's pathology. Apolipoprotein E4, the strongest genetic risk factor for late-onset disease, appeared to impair Aβ clearance. These observations formed a coherent story: an imbalance in Aβ production and clearance initiated plaques, which then triggered tau hyperphosphorylation, neuronal death, and cognitive decline. The framework explained why plaques were a neuropathological hallmark and offered a clear target for therapy. ^[2][4][13]

A 2006 Nature paper claimed to have isolated a specific oligomer called Aβ*56 from transgenic mice and demonstrated that injecting it into rats produced memory impairment. The work received immediate attention, with the journal and Alzforum describing the oligomer as a star suspect. It became one of the most cited pieces of evidence that soluble amyloid species, rather than plaques alone, drove toxicity. The paper's prestige and apparent mechanistic detail made the hypothesis seem experimentally grounded. Subsequent research built on it for more than a decade. ^[6]

Yet mounting evidence challenges aspects of the original story. Amyloid plaque burden correlates only weakly with cognitive impairment compared with neurofibrillary tangles, and some individuals harbor abundant plaques at autopsy without ever developing dementia. Clinical trials of anti-amyloid antibodies have cleared plaques but produced only modest or statistically insignificant effects on cognition. A substantial body of experts now questions whether Aβ is the primary driver in sporadic Alzheimer's or merely one contributor among several. Critics argue that the genetic evidence from rare early-onset cases may not generalize to the far more common late-onset form. ^{[8][14][16][17]}

A 2009 Nature paper from Genentech researchers reported that the death receptor DR6 binds N-APP to promote neuronal pruning and death in Alzheimer's models. The claim appeared credible because it came from a prestigious journal and seemed to link amyloid processing directly to neurodegeneration. Genentech launched a drug program based on the findings. Internal replication attempts later failed, genetic tests in mouse models showed no effect, and image anomalies were identified in key figures. The paper was retracted in 2023 after more than a decade of resistance. ^[5][15]

▶ Supporting Quotes (46)

“For decades, Alzheimer’s research has been shaped by the dominance of a single theory, the amyloid hypothesis. It holds that amyloid proteins prompt a cascade of biochemical changes in the brain that cause dementia.”— Beyond the Alzheimer's Research Fraud

“The entrenchment of the amyloid hypothesis has fostered a kind of groupthink where grants, corporate riches, career advancement and professional reputations often depend on a central idea largely accepted by institutional authorities on faith.”— Beyond the Alzheimer's Research Fraud

“The amyloid cascade hypothesis proposes that accumulation of Aβ results from the imbalance between Aβ production and clearance in the brain, and the formation of extracellular Aβ plaques is a driving force triggering tau pathology, which is followed by neuronal death”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“elevated accumulation of Aβ has been detected in the brains of symptomatic individuals from families carrying autosomal dominant mutations in presenilin 1, presenilin 2, and amyloid beta precursor protein genes compared with the brains of non-carriers”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Toxic Aβ species are believed to accelerate the formation of pathological tau by altering the activities of protein kinases and phosphatases that mediate tau phosphorylation and by inducing tau misfolding. Thus, a co-dependence exists between Aβ and tau, with Aβ upstream of tau in AD pathogenesis and serving as the trigger for tau conversion. This relationship has been described by the amyloid cascade hypothesis and has become a widely held theory of AD as an amyloid-driven tauopathy”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates Aβ.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Duplication of the wild‐type APP gene in Down's syndrome leads to Aβ deposits in the teens, followed by microgliosis, astrocytosis, and neurofibrillary tangles typical of AD.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“The 2009 Nature paper generally describes research directed at understanding the involvement of certain proteins, including those known as DR6 and APP, in neuronal death and degeneration with possible implications for Alzheimer’s Disease.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“This expert concluded that two sets of figures, Figures 1d and 5e and Supplementary Figures 9c and 17c, include duplicate images. The expert also concluded that a Western blot panel for Caspase 6 in Supplementary Figure 6d appears to include a composite of two images.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“In the brains of Ashe’s transgenic mice, the UMN team discovered a previously unknown oligomer species, dubbed Aβ*56 (pronounced “amyloid beta star 56”) after its relatively heavy molecular weight compared with other oligomers. The group isolated Aβ*56 and injected it into young rats. The rats’ capacity to recall simple, previously learned information—such as the location of a hidden platform in a maze—plummeted.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“scores of his lab studies at UCSD and NIA are riddled with apparently falsified Western blots—images used to show the presence of proteins—and micrographs of brain tissue. Numerous images seem to have been inappropriately reused within and across papers, sometimes published years apart in different journals, describing divergent experimental conditions.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“His work on topics including alpha-synuclein—a protein linked to both diseases—continues to influence basic and clinical science... Masliah’s work, for example, helped win a nod from the U.S. Food and Drug Administration (FDA) for clinical trials of an antibody called prasinezumab for Parkinson’s.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“We reviewed the data of past failures to determine how aducanumab and lecanemab might differ from the rest of this class of drugs. Specifically, whether the differences between treatment and placebo are different.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“We focused on two outcome measures that were most frequently reported ‐ CDR‐SB and ADAS‐Cog. Nearly all trials reported the post‐treatment difference between drug and placebo”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“On a scale where a higher score is “worse,” a negative (‐) difference “favors” treatment (lower score – higher score = ‐ value).”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Mutations within and immediately flanking the Aβ region of APP cause aggressive forms of FAD.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Confirmation that presenilin is the catalytic site of γ‐secretase has provided a linchpin: all dominant mutations causing early‐onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin)”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Apolipoprotein E4, which predisposes to AD in > 40% of cases, has been found to impair Aβ clearance from the brain.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Until now, it was believed that neurodegeneration in Alzheimer's, especially that affecting the medial temporal lobe of the brain, a region essential for memory function, occurred only when two key proteins were present: beta amyloid and tau. However, this new work suggests that the accumulation of beta amyloid can, on its own, trigger brain damage and memory loss in the early stages, even without the presence of high levels of tau.”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“Since the amyloid hypothesis became dominant in 2006 due to a doctored study”— Beyond the Alzheimer's Research Fraud

“Billions spent, decades lost: the cautionary tale of how Alzheimer’s research went all-in on a bad bet. Another way to understand how groundbreaking these results were thought to be at the time is to simply follow the money. Within a year, Athena Neurosciences, where Games worked, was acquired by Elan Corp. for a staggering $638 million... The PDAPP mouse had transformed from laboratory marvel to the cornerstone of a billion-dollar strategy.”— The Internet You Missed: A 2025 Snapshot

“KOH, J.Y., BETA-AMYLOID PROTEIN INCREASES THE VULNERABILITY OF CULTURED CORTICAL-NEURONS TO EXCITOTOXIC DAMAGE, BRAIN RESEARCH 533: 315 (1990).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“MASTERS, C.L., AMYLOID PLAQUE CORE PROTEIN IN ALZHEIMER-DISEASE AND DOWN SYNDROME, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 82: 4245 (1985).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“PIKE, C.J., INVITRO AGING OF BETA-AMYLOID PROTEIN CAUSES PEPTIDE AGGREGATION AND NEUROTOXICITY, BRAIN RESEARCH 563: 311 (1991).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“In 1984, Aβ and its amino acid sequence were reported for the first time as a primary constituent of meningovascular polymorphic deposits in patients with Down Syndrome; the full sequence of parenchymal Aβ plaque core was found to be identical to the peri-vascular component previously described except that the latter mainly extends to the 42nd residue. Subsequently, the APP gene was sequenced, corroborating that Aβ is a by-product of the enzymatic processing of APP.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Eventually, dense Aβ aggregates were described as the main constituent of neocortical neuritic plaques, characterizing brain aging and constituting a pathological hallmark of AD along with tau neurofibrillary tangles (NTFs).”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“brain Aβ accumulation appears to be upstream to other pathomechanistic alterations of the biological continuum of AD, including the spreading of NTFs, and involvement of neuronal and synaptic loss.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Large-scale genetic analyses conducted in datasets of informative monogenic EOAD pedigrees identified highly penetrant mutations in the three genes—the APP gene and the presenilin 1 and 2 (PSEN1 and PSEN2) genes. These mutations are transmitted through autosomal dominant inheritance (i.e., autosomal dominant Alzheimer’s disease or ADAD). In mouse models of ADAD each monogenic mutation causes Aβ dyshomeostasis, with protein misfolding, aggregation, and accumulation in brain parenchymal Aβ plaques.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“The hypothesis is supported by the molecular genetics of the early-onset familial forms of AD, caused by inherited dominant mutations in the APP, PS1 or PS2 genes. Some 300 pathogenic mutations have been identified which cause AD at age 22–60”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“PS1 has the most mutations, which can result in increased, decreased or no Aβ peptide production, or in increased or decreased Aβ42/40 ratio (see below), Aβ42 being the more hydrophobic peptide prone to aggregation and amyloid formation”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“The retraction notice also acknowledged that four panels appeared to have been reused to represent different experiments, and a fifth panel appeared to contain a blot partially duplicated from a sixth panel. There were also unspecified errors in “certain biostatistical calculations underlying some figures,””— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“Using the amino acid sequence corresponding to Aβ [...], a precursor gene cDNA to Aβ (the amyloid precursor protein, APP) was sequenced [...]. This finding had compelling implications in view of the observation many individuals with trisomy 21 (Down’s Syndrome) reach the neuropathogical criteria for AD by age 40. [...] Surprisingly, the fact that not all people with Down’s syndrome develop AD, despite plaques and increased Aβ expression, did not receive significant attention.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“Although some changes to the hypothesis have occurred since the original publications, notably a shift toward defining soluble Aβ oligomers as the toxic agent, rather than plaques, the theory and the way data is interpreted have remained largely the same, i.e. Aβ accumulation as oligomers or plaques triggers AD. [...] questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“In the brains of Ashe’s transgenic mice, the UMN team discovered a previously unknown oligomer species, dubbed Aβ*56... The group isolated Aβ*56 and injected it into young rats. The rats’ capacity to recall simple, previously learned information... plummeted.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“This led to the amyloid cascade hypothesis proposed in a seminal paper by John Hardy and Gerrald Higgins (1992). They posited that beta-amyloid was the causative agent of AD... Yet the amyloid cascade hypothesis has been the prevailing idea in the field for 30 years and attracted the lions’ share of the billions of research dollars.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“some authors suggest that the “amyloid cascade hypothesis” may be incorrect or insufficient to fully explain the pathogenesis of sporadic Alzheimer Disease (AD).”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“anti-amyloid treatments must be administered during the early stages of the disease process, i.e., before the establishment of severe neurodegeneration secondary to AD pathology”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“a vaporous exhalation formerly believed to cause disease”— Definition of MIASMA

“Last year every man, woman and child in the United States consumed 125 pounds of fat... Reduce overall fat consumption from approximately 40 to 30 percent of energy intake.”— Dietary Goals for the United States

“Autophagy normally clears proteins such as amyloid beta from cells, but if that process slows in older adults, amyloid beta may accumulate”— Autophagy in Alzheimer disease pathogenesis and its therapeutic values

“the dominant theory that has guided researchers’ efforts this century — that Alzheimer’s symptoms are caused by the buildup of proteins called “amyloid plaques” in the brain — is now in serious question. That might explain why, as Piller notes, a recent meta-analysis of the available research found no evidence that any of the available Alzheimer’s drugs cause noticeable improvements”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“On the basis of a new study just published in JAMA, donanemab is being treated as a major turning point in the fight against this neurodegenerative disease”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

How It Spread

The amyloid hypothesis spread through prestigious peer-reviewed journals that lent it credibility and made it the default framework for grant proposals and career advancement. Science published the original cascade hypothesis paper, while Nature carried both the 2006 oligomer study and the 2009 DR6 paper. These venues reached thousands of scientists and shaped what questions seemed worth asking. Review articles by leading figures synthesized the genetic, pathological, and biomarker data into a unified narrative that dominated citations for decades. The steady accumulation of papers created an impression of consensus even as clinical results lagged. ^[2][4][6]

Funding incentives reinforced the pattern. The National Institutes of Health directed roughly half its Alzheimer's budget toward amyloid projects, and pharmaceutical companies invested billions in anti-amyloid pipelines. Grants, promotions, and corporate acquisitions flowed more readily to work that aligned with the dominant model. Researchers who pursued alternative explanations sometimes found their manuscripts rejected or their funding harder to obtain. The system rewarded conformity and punished dissent, producing a steady stream of papers that cited the same foundational claims. ^[1][7][14]

Media coverage and institutional press releases amplified the message. When the 2006 Nature paper appeared, headlines announced a star suspect in Alzheimer's. Genentech highlighted the 2009 work in shareholder letters and investor presentations. Journals and universities issued optimistic statements about progress toward disease-modifying therapies. The narrative of amyloid as the root cause became conventional wisdom in both scientific and popular accounts, even as trial after trial failed to deliver meaningful clinical benefit. ^[6][15]

A small number of dissenters questioned the emphasis on amyloid, but their concerns gained little traction until investigative reporting exposed image manipulation in high-profile papers. The conformity pressure had been strong enough to keep the field focused on one target for more than 25 years. ^[1][29]

▶ Supporting Quotes (38)

“The supremacy of that hypothesis has exerted enormous pressure toward scientific conformity. … It’s easier to publish dubious science that aligns with conventional wisdom.”— Beyond the Alzheimer's Research Fraud

“Scientists, funders and drug companies have struggled to justify billions in costs and careers pursuing dead-end paths.”— Beyond the Alzheimer's Research Fraud

“Measurement of fibrillar amyloid has been pivotal to the development and approval of disease-slowing treatments.”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“In Section 5, we present statistical analyses from the recent clinical development programs for AD that provide evidence supporting the reduction in Aβ plaques as a surrogate endpoint for clinical benefit.”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Since molecular studies of AD began in earnest in the early 1980s, thousands of scientists and healthcare professionals have delved into all aspects of this complex, multifactorial syndrome”— The amyloid hypothesis of Alzheimer's disease at 25 years

“the publication of the 2009 Nature paper”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“At Genentech, drug discovery programs receive regular scientific reviews by the RRC.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“An accompanying editorial in Nature called Aβ*56 “a star suspect” in Alzheimer’s. Alzforum, a widely read online hub for the field, titled its coverage, “Aβ Star is Born?””— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“His roughly 800 research papers... have made him one of the most cited scientists in his field... His output, as well as the number of citations to his papers, place him among the world’s top 10 scientists in certain subfields”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“As a division director, Masliah would hold sway over NIA’s neuroscience funding... institute and division directors can fund preferred projects, such as studies of amyloid, the brain protein linked to Alzheimer’s disease, over better scoring competitors.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“Nearly all trials reported the post‐treatment difference between drug and placebo, i.e., the difference between scores of the treatment relative to the placebo at the end of the trial.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“The amyloid (or Aβ) hypothesis (Beyreuther & Masters, 1991; Hardy & Allsop, 1991; Selkoe, 1991; Hardy & Higgins, 1992) has become the dominant model of AD pathogenesis”— The amyloid hypothesis of Alzheimer's disease at 25 years

“This finding, published in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“data from Alfa participants have been matched to the EPAD validation cohort, which has no symptoms of Alzheimer's disease or presence of tau protein.”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“Over the past 25 years, Alzheimer’s research has suffered a litany of ostensible fraud and other misconduct by world-famous researchers and obscure scientists alike, all trying to ascend in a brutally competitive field.”— Beyond the Alzheimer's Research Fraud

“Pharmaceutical giants, small biotechs, and research organizations and foundations placed enormous bets on amyloid—bets that, time and again, failed to pay off.”— The Internet You Missed: A 2025 Snapshot

“KANG, J, THE PRECURSOR OF ALZHEIMERS-DISEASE AMYLOID-A4 PROTEIN RESEMBLES A CELL-SURFACE RECEPTOR, NATURE 325: 733 (1987).”— Alzheimer's Disease: The Amyloid Cascade Hypothesis

“In the last 25 years, translational studies—including experimental animal and human neuropathological, genetic, and in vivo biomarker-based evidence—support a descriptive hypothetical model of AD pathophysiology characterized by the upstream brain accumulation of Aβ species and plaques, which precedes spreading of tau, neuronal loss and ultimately clinical manifestations by up to 20–30 years.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Neuropathological studies, confirmed in vivo by recent quantitative neuroimaging investigations, indicate a spatial-temporal evolution of brain Aβ accumulation that occurs initially in cerebral regions with neuronal populations at high metabolic bio-energetic activity rates (such as association cortices) and spreads from neocortex to allocortex to brainstem, eventually reaching the cerebellum.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Formulated in 1991-1992, the hypothesis has dominated AD research, drug discovery, and clinical trial studies ever since”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Genentech’s public rollout lauded the study as a long-awaited breakthrough in combating Alzheimer’s. “Because of this research,” Genentech’s 2009 annual letter to shareholders read,”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“On a slide listing the company’s “key scientific discoveries,” only this research appeared highlighted in blue.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“The amyloid hypothesis has become difficult to challenge because it is so often the lens through which peer reviewers, granting bodies and pharmaceutical companies view, judge and support AD research. Thus new non-amyloid data tends to be couched in terms that place it within the amyloid hypothesis and many authors tacitly ignore valid, but quite different, interpretations.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“The Nature paper has been cited in about 2300 scholarly articles—more than all but four other Alzh”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“Yet the amyloid cascade hypothesis has been the prevailing idea in the field for 30 years and attracted the lions’ share of the billions of research dollars.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“A swift analysis of the available trials involving anti-amyloid immune compounds prompts that the clinical benefits have fallen short of expectations, despite accomplishing the expected biological outcome, i.e., amyloid clearance from the brain.”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“For him, miasma had the same meaning that it did when it first appeared in English in the 1600s: an emanation of a vaporous disease-causing substance.”— Definition of MIASMA

“We must acknowledge and recognize that the public is confused about what to eat to maximize health. If we as a Government want to reduce health costs and maximize the quality of life for all Americans, we have an obligation to provide practical guides”— Dietary Goals for the United States, Second Edition

“My hope is that this report will perform a function similar to that of the Surgeon General's Report on Smoking.”— Dietary Goals for the United States

“USDA began addressing the role of fats, sugars, and sodium in risks for chronic diseases in its 1979 publication, Food... This guide modified the Basic Four to high- light a fifth food group—fats, sweets, and alcoholic beverages—target- ed for moderation.”— Dietary Recommendations and How They Have Changed Over Time

“He and his wife Margaret wrote two bestselling cookbooks: Eat Well and Stay Well (1959), and How to Eat Well and Stay Well the Mediterranean Way (1975).”— Ancel Keys

“The purpose of this press conference is to release a Nutrition Committee study entitled Dietary Goals for the United States... My hope is that this report will perform a function similar to that of the Surgeon General’s Report on Smoking.”— Dietary Goals for the United States

“The impact of television food advertising... Advertising and low-income consumers.”— Dietary Goals for the United States

“In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more”— In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis

“The strategy adopted by many mainstream liberals ... — effectively, plugging our ears and chanting “trust the science” over and over ... “Science is real,” you will see on signs planted in front of many liberal homes.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“donanemab is being treated as a major turning point in the fight against this neurodegenerative disease, and it comes …”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

Resulting Policies

The FDA granted accelerated approval to aducanumab in 2021 and to lecanemab in 2023 on the basis of their ability to reduce amyloid plaques, even though the cognitive benefits were modest and the drugs carried risks of brain swelling and bleeding. Regulators accepted plaque clearance as a surrogate endpoint reasonably likely to predict clinical benefit under a pathway established in 1992 for serious conditions. The decisions kept the amyloid framework embedded in regulatory policy despite repeated trial failures on primary cognitive endpoints. ^[17]

The National Institutes of Health allocated approximately 1.6 billion dollars per year, about half its Alzheimer's budget, to projects based on the amyloid hypothesis. This funding priority influenced what kinds of studies received support and helped sustain the model in academic laboratories and clinical trial networks. Grants flowed to research that assumed Aβ reduction would translate into patient benefit. ^[6]

Clinical development programs tested anti-amyloid antibodies such as solanezumab, crenezumab, and aducanumab in patients with mild to moderate disease, guided by the belief that removing amyloid would slow decline. These trials enrolled thousands of participants and shaped the design of later studies that moved earlier in the disease course. The FDA's approval of two drugs reinforced the strategy even after many earlier compounds had failed. ^[4][18]

European regulators took a different path. The European Medicines Agency rejected both aducanumab and lecanemab, citing insufficient evidence of meaningful clinical benefit relative to the safety risks. The contrasting decisions highlighted ongoing disagreement about whether the amyloid hypothesis justifies widespread use of these therapies. ^[17]

▶ Supporting Quotes (18)

“The anti-amyloid antibody drugs approved in the United States cost tens of thousands of dollars per patient per year, yet they slow cognitive decline so minutely that many doctors call the benefits imperceptible.”— Beyond the Alzheimer's Research Fraud

“The FDA defines a surrogate endpoint as a marker or other measure that is not itself a direct measure of clinical benefit but rather is known to predict clinical benefit (used to support full approval) or is reasonably likely to predict clinical benefit (used to support accelerated approval)”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects.”— The amyloid hypothesis of Alzheimer's disease at 25 years

“whose budget—$2.6 billion in the last fiscal year—dwarfs the rest of NIA combined.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“recent trials of three different Aβ antibodies (solanezumab, crenezumab, and aducanumab) have suggested a slowing of cognitive decline in post hoc analyses of mild AD subjects”— The amyloid hypothesis of Alzheimer's disease at 25 years

““In recent years, the first drugs have been approved to reduce the accumulation of beta amyloid in the brain of people in the early stages of Alzheimer's.”— Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer's

“This pathophysiological model has supported a considerable effort to develop therapeutic compounds targeting the Aβ pathway to slow AD progression in early clinical stages. More recently, several anti-Aβ therapeutic pipelines have been expanded to preclinical stages of AD, when the expected success rate of compounds with putative biological effects is higher.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Two identical Phase 3 clinical trials, EMERGE and ENGAGE, evaluated the safety and efficacy of aducanumab in the treatment of Alzheimer’s disease.”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Roche’s offer increased from $86.50 to $95 a share, a difference of roughly $4 billion.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“The amyloid hypothesis has driven drug development strategies for Alzheimer's disease for over 20 years.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“lecanemab, marketed as Leqembi, was rejected by the European Medicines Agency (EMA) in July 2024—after approval by the US Food and Drug Administration (FDA) a year earlier. The approval of lecanemab mirrors the fate of the first AAD called aducanumab... approved by the FDA.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“Results from failed phase 3 trials indicate that the interventions are ineffective in patients with AD who already present symptoms of full-blown dementia, even at mild to moderate stages.”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“The impact of television food advertising_______________________ 59 Advertising and low-income consumers_________________________ 63 Lack of nutrition information______________________ 64”— Dietary Goals for the United States, Second Edition

“Recommendations for governmental action... Action is needed to determine how changes can be made regarding the content of nutritional information provided to the public; the kinds of foods produced; how foods are processed and advertised.”— Dietary Goals for the United States

“We’re two decades and many billions of dollars into the modern era of Alzheimer’s research ... Trump signed an executive order which froze the disbursement of National Science Foundation funds.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“donanemab, which the FDA is likely to decide whether to approve by the end of the year”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

Harm Caused

Billions of dollars in research funding were directed toward amyloid-targeting therapies over more than two decades, yet the drugs that reached approval slow cognitive decline by amounts that many clinicians describe as imperceptible to patients and families. The therapies carry documented risks of brain swelling, microhemorrhages, and in rare cases death. Resources that might have gone to other biological targets were instead spent on repeated attempts to clear plaques. ^[1][8][14]

Patients endured years of therapeutic disappointment while alternative approaches received less attention. Lithium research, for example, was sidelined for nearly two decades despite emerging signals that brain lithium levels are reduced in mild cognitive impairment and Alzheimer's. The focus on amyloid left other plausible mechanisms underfunded and understudied. ^[1]

Pharmaceutical companies lost substantial sums on failed programs. Elan spent two billion dollars on four amyloid therapeutics that reached clinical testing and ultimately went defunct. Genentech devoted years of scientist time and corporate resources to a DR6 program that was terminated after the underlying biology could not be reproduced. These financial losses were accompanied by opportunity costs in other areas of neurodegeneration research. ^[12][15]

Public trust in the scientific enterprise suffered as investigative reports revealed manipulated images in influential papers that had shaped funding and policy. The scandals raised questions about how many other results in the field might rest on similarly shaky foundations. A growing number of observers worry that the episode has delayed genuine progress against a disease that already costs the United States roughly one billion dollars per day in care. ^[6][29]

▶ Supporting Quotes (27)

“doctors, patients and their loved ones have endured decades of therapeutic failures stemming from it, despite billions of dollars spent in grants and investments.”— Beyond the Alzheimer's Research Fraud

“The drugs are also not benign, posing risks of death or serious brain injury, and they can shrink the brain faster than Alzheimer’s itself.”— Beyond the Alzheimer's Research Fraud

“a lot of other potential treatments have been given short shrift for research dollars.”— Beyond the Alzheimer's Research Fraud

“The FDA-approved drugs encainide, flecainide, moricizine, and zidovudine had been based on candidate surrogate endpoints; however, later postmarketing trials revealed that these surrogate endpoints were poor predictors of clinically relevant outcomes”— A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s disease

“Numerous clinical trials of anti‐amyloid agents have not met their pre‐specified endpoints”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Genentech’s termination of the DR6 drug discovery program marked the end of many years of challenging and often frustrating research that many hoped would culminate in a treatment for Alzheimer’s Disease. Many scientists who worked on the project were disheartened by having devoted substantial time and energy to a program whose underlying biology was ultimately proven wrong.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“Schrag’s work, done independently of Vanderbilt and its medical center, implies millions of federal dollars may have been misspent on the research—and much more on related efforts.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

““The immediate, obvious damage is wasted NIH funding and wasted thinking in the field because people are using these results as a starting point for their own experiments,” says Stanford University neuroscientist Thomas Südhof”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“But in a trial of 316 Parkinson’s patients, reported in 2022 in The New England Journal of Medicine, prasinezumab showed no benefit compared with a placebo. And volunteers given infusions of the antibody suffered from far more side effects such as nausea and headaches than those in a placebo group”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

““The volume of papers and resources involved are enormous—as is Dr. Masliah’s leadership and influence on the field, including drug development pipelines,””— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“Amyloid hypothesis: 20 years of failure in Alzheimer’s research”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Numerous clinical trials of anti‐amyloid agents have not met their pre‐specified endpoints”— The amyloid hypothesis of Alzheimer's disease at 25 years

“despite billions of dollars spent in grants and investments. … The anti-amyloid antibody drugs approved in the United States cost tens of thousands of dollars per patient per year, yet they slow cognitive decline so minutely that many doctors call the benefits imperceptible. The drugs are also not benign, posing risks of death or serious brain injury, and they can shrink the brain faster than Alzheimer’s itself. Since the amyloid hypothesis became dominant in 2006 due to a doctored study, a lot of other potential treatments have been given short shrift for research dollars.”— Beyond the Alzheimer's Research Fraud

“doctors, patients and their loved ones have endured decades of therapeutic failures stemming from it”— Beyond the Alzheimer's Research Fraud

“By the time Elan became defunct in 2013, they had sponsored not one, not two, but four failed Alzheimer's disease therapeutics, all based on the amyloid cascade hypothesis, hemorrhaging $2 billion in the process. And they weren't alone. Pharmaceutical giants, small biotechs, and research organizations and foundations placed enormous bets on amyloid—bets that, time and again, failed to pay off.”— The Internet You Missed: A 2025 Snapshot

“While research and physician communities have raised theoretical and conceptual questions on the scientific appeal of Aβ-targeting therapeutic development due to the failures of AD drug clinical trials, anti-Aβ compounds are continually investigated with promising progress of several late-stage development agents towards regulatory approval steps.”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“Worse still, the drugs often harmed the study volunteers, causing serious health problems including infections, skin cancers, cerebral vascular edema, cerebral microhemorrhages, severe cognitive decline, and death”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Current AD drug therapies with acetylcholine esterase inhibitors (donepezil, galantamine, and rivastigmine), or memantine, an inhibitor of NMDA receptor and synaptic glutamate signaling, only provide symptomatic and temporary relief; they do not stop or slow the course of AD progression”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Roche’s offer increased from $86.50 to $95 a share, a difference of roughly $4 billion.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“This retraction is Tessier-Lavigne’s fourth in as many months, a stunning turn of events for a researcher of his stature.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“We elaborate on and update arguments for and against the amyloid hypothesis with new data and interpretations, and consider why the amyloid hypothesis may be failing therapeutically.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“Schrag’s work... implies millions of federal dollars may have been misspent on the research—and much more on related efforts. Some Alzheimer’s experts now suspect Lesné’s studies have misdirected Alzheimer’s research for 16 years.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“Clarity AD also reported that most amyloid-related imaging abnormalities (ARIA)—that can indicate cerebral edema or lesions—occurred in the first 6 months of treatment.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“the repeated failures of anti-amyloid therapies.”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“Unresolved issues in the field include the presence of Ab deposition in cognitively normal individuals, the weak correlation between plaque load and cognition”— In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis

“We’re two decades and many billions of dollars into the modern era of Alzheimer’s research, and we have precious little to show for it — a particularly dire state of affairs given that this dread condition is only going to hit us harder as America’s population continues to age.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

Downfall

The assumption began to lose its grip when independent investigators identified apparent image manipulation in the 2006 Nature paper that had helped establish the toxic oligomer story. Matthew Schrag flagged dozens of duplicated and composite figures in 2021. Elisabeth Bik and other image analysts confirmed the anomalies. Nature issued an expression of concern, and the University of Minnesota opened a review. The episode suggested that a foundational piece of evidence had been unreliable from the start. ^[6]

A separate high-profile paper from 2009 was retracted in December 2023 after Stanford's investigation found that key experiments could not be reproduced and that image anomalies had gone uncorrected for more than a decade. Genentech had terminated its related drug program in 2012 after its own scientists failed to replicate the DR6 binding results. The retraction of work once touted in shareholder presentations added to the accumulating doubts. ^[5][15]

Large-scale analyses of clinical trial data showed that anti-amyloid antibodies produced only tiny average differences on cognitive scales. Bootstrap resampling of CDR-SB and ADAS-Cog results yielded confidence intervals that crossed zero, indicating no reliable clinical benefit despite successful plaque removal. The gap between biomarker success and patient outcomes became harder to dismiss. ^[8]

By the mid-2020s a substantial body of experts viewed the amyloid hypothesis as a working hypothesis at best, no less but certainly no more. Alternative explanations involving inflammation, metabolic factors, and other proteins gained renewed attention. The field had not abandoned amyloid entirely, but the confident assertion that it was the primary cause had given way to a more cautious and pluralistic view of Alzheimer's disease. ^[14][26]

▶ Supporting Quotes (35)

“Since the amyloid hypothesis became dominant in 2006 due to a doctored study”— Beyond the Alzheimer's Research Fraud

“Over the past 25 years, Alzheimer’s research has suffered a litany of ostensible fraud and other misconduct by world-famous researchers and obscure scientists alike”— Beyond the Alzheimer's Research Fraud

“Li was the only one that was significantly reduced in the brain in individuals with mild cognitive impairment (MCI), a precursor to AD.”— Beyond the Alzheimer's Research Fraud

“Amyloid plaque burden correlates much less well with degree of cognitive impairment than do neurofibrillary tangle counts”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Many humans show sometimes abundant Aβ deposits at death but were not noticeably demented”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Some human neuropathological studies suggest tangles may precede amyloid plaques”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Genentech scientists and research associates had difficulty reproducing certain results reported in the 2009 Nature paper, in particular, the binding interaction between DR6 and N-APP”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“The genetic experiments performed at Genentech showed that in two different mouse models of Alzheimer’s Disease, the neurologic features associated with that disease (for example, deposition of amyloid plaques, synaptic loss, or cognitive behavior defects) were not dependent on DR6. On that basis, the RRC terminated the DR6 drug discovery program in 2012.”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“The results of the genetic experiments – at Genentech and Rockefeller – were reported in a pair of papers submitted to the Journal of Neuroscience in 2013 and published in 2014 ... Upon the publication of those papers, the scientific community began to discuss how the results and conclusions reported there differed in several respects from those reported in the 2009 Nature paper”— Findings of 2023 Genentech Review of 2009 Nature Paper and Related Research

“A 6-month investigation by Science provided strong support for Schrag’s suspicions and raised questions about Lesné’s research... two, including Nature last week, have published expressions of concern about papers by Lesné.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“A Science investigation has now found... a neuroscientist and forensic analysts... produced a 300-page dossier revealing a steady stream of suspect images between 1997 and 2023 in 132 of his published research papers.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“The enormity of apparent problems described in the Masliah dossier stunned 11 neuroscientists who agreed to review it for Science... All 11 who reviewed the dossier agree that all his problem papers should be investigated by NIH, scholarly journals, funders, and UCSD.”— Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?

“The estimated bootstrap mean and 95%CI for differences between placebo and drug, for CDR‐SB and for ADAS‐Cog were: CDR‐SB; mean (95%CI) = ‐0.08 (‐0.31 to +0.22), range of differences = ‐0.70 to 1.30; ADAS‐Cog; mean (95%CI) = ‐0.53 (‐1.03 to +0.22), range of differences = ‐1.60 to +4.74.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“The cumulative mean changes for CDR‐SB were ‐0.08; for ADAS‐Cog it was ‐0.53, with both 95%CI including zero. The score range for CDR‐SB is 0 to 18; the range for ADAS‐Cog is 0 to 70/90. These mean differences across the many trials conducted cannot be considered to be either clinically or statistically significant.”— Amyloid hypothesis: 20 years of failure in Alzheimer’s research

“Amyloid plaque burden correlates much less well with degree of cognitive impairment than do neurofibrillary tangle counts”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Many humans show sometimes abundant Aβ deposits at death but were not noticeably demented”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Some human neuropathological studies suggest tangles may precede amyloid plaques”— The amyloid hypothesis of Alzheimer's disease at 25 years

“Over the past 25 years, Alzheimer’s research has suffered a litany of ostensible fraud and other misconduct by world-famous researchers … During years of investigative reporting, I’ve uncovered many such cases … Lithium deficiency and the onset of Alzheimer’s disease … Replacement therapy with lithium orotate … prevents pathological changes and memory loss in AD mouse models”— Beyond the Alzheimer's Research Fraud

“Critical evaluation of the Aβ pathway in the sole context of clinical trials is a worthy topic for discussion and have been discussed frequently. Critical evaluation of evidence independent of clinical trial results of anti-Aβ drugs can provide the rationale and validation of the disease relevance of the Aβ pathway”— The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatry

“The amyloid cascade hypothesis in Alzheimer’s disease is also not supported by the ambiguous, quite controversial results of clinical trials of drugs with β- or γ-secretase inhibitors or with anti-Aβ antibodies”— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“Brain amyloid PET scans of cognitively unimpaired people often look the same as the PET scans of people with AD. At brain autopsy, 30% of people without AD had typical amyloid formation characteristics of AD brains. In short, as David Snowdon put it in his great ‘Nun Study’ in 1997: “Brain amyloid is not synonymous with dementia””— The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?

“By 2012, it had become clear to researchers both inside Genentech and at rival pharmaceutical companies that the research in the Tessier-Lavigne paper was not reproducible.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“Concerns about Tessier-Lavigne’s research first emerged in 2015 on a scientific forum called PubPeer.”— Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistance

“We note several unresolved issues in the field including the presence of Aβ deposition in cognitively normal individuals, the weak correlation between plaque load and cognition, questions regarding the biochemical nature, presence and role of Aβ oligomeric assemblies in vivo, the bias of pre-clinical AD models toward the amyloid hypothesis and the poorly explained pathological heterogeneity and comorbidities associated with AD. We also illustrate how extensive data cited in support of the amyloid hypothesis, including genetic links to disease, can be interpreted independently of a role for Aβ in AD.”— Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

“A leading independent image analyst and several top Alzheimer’s researchers... reviewed most of Schrag’s findings at Science’s request. They concurred with his overall conclusions, which cast doubt on hundreds of images, including more than 70 in Lesné’s papers.”— Potential fabrication in research images threatens key theory of Alzheimer’s disease

“The recent rejection of lecanemab by the European Medicines Agency (EMA) in July 2024... The controversy centres around the interpretation of clinical trial results over both safety and efficacy.”— The controversy around anti-amyloid antibodies for treating Alzheimer’s disease

“at the dementia stage of AD, it may be too late (in the disease continuum) for amyloid removal to yield any clinical improvement.”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“the duration of the intervention in most trials may have been insufficient to yield good discrimination between experimental and control groups”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“other sources of biological heterogeneity may have endured in study samples, rendering heterogeneous treatment groups and, hence, mixing responders with non-responders.”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“Improvements in immunotherapeutic compounds per se are likely necessary. The drugs tested for treating AD target distinct epitopes and conformations of amyloid-beta”— What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

“Nowadays, we know germs are the source of infection, so we're more likely to use the newer, more figurative sense of miasma”— Definition of MIASMA

“Although the still-unfolding story of dietary fat proved more complex than Keys envisioned.”— Ancel Keys

“This fraud was uncovered not by journal editors or peer-reviewers ... but by unpaid sleuths “who use pseudonyms to post comments” online ... Piller’s book, which was released February 4, tells the story of a wild and heartbreaking goose-chase.”— Trump Or No, Science Badly Needs To Look Inward And Heal Itself

“This Is A Low Bar For Alzheimer’s Researchers To Trip Over A bit more about those “easy” problems scientists stubbornly refuse to solve”— This Is A Low Bar For Alzheimer’s Researchers To Trip Over

Sources

[1]
Beyond the Alzheimer's Research Fraudreputable_journalism
Steve Sailer · Steve Sailer Substack · 2025-08-13
[2]
Alzheimer's Disease: The Amyloid Cascade Hypothesispeer_reviewed
Science
[3]
A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer’s diseasepeer_reviewed
Tianle Chen, R Matthew Hutchison et al. · J Prev Alzheimers Dis · 2026-01-01
[4]
The amyloid hypothesis of Alzheimer's disease at 25 yearspeer_reviewed
Dennis J Selkoe, John Hardy · EMBO Mol Med · 2016-03-29
[5]
Findings of 2023 Genentech Review of 2009 Nature Paper and Related Researchprimary_source
Genentech · Genentech · 2023-04-06
[6]
Potential fabrication in research images threatens key theory of Alzheimer’s diseasereputable_journalism
Charles Piller · Science · 2022-08-04
[7]
Did a top NIH official manipulate Alzheimer’s and Parkinson’s studies for decades?reputable_journalism
Science
[8]
Amyloid hypothesis: 20 years of failure in Alzheimer’s researchpeer_reviewed
Lloyd Tran, Zung Vu Tran · Alzheimer's & Dementia · 2025-01-09
[10]
Amyloid beta accumulation confirmed to cause early brain damage in Alzheimer'sprimary_source
Barcelonaβeta Brain Research Center · Pasqual Maragall Foundation · 2025-02-03
[11]
Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer’s continuum: evidence across two independent cohortspeer_reviewed
Cacciaglia R, Falcón C, Benavides GS, et al.; for the ALFA study · Alzheimer’s Dement · 2025
[12]
The Internet You Missed: A 2025 Snapshotopinion
Erik Hoel · The Intrinsic Perspective · 2025-08-13
[13]
The Amyloid-β Pathway in Alzheimer’s Disease - Molecular Psychiatrypeer_reviewed
Molecular Psychiatry · 2021-10-26
[14]
The Amyloid Cascade Hypothesis in Alzheimer’s Disease: Should We Change Our Thinking?peer_reviewed
Markku Kurkinen, Michał Fułek, Katarzyna Fułek, Jan Aleksander Beszłej, Donata Kurpas, Jerzy Leszek · Biomolecules · 2023-03-01
[15]
Blockbuster Alzheimer’s paper retracted by former Stanford president after a decade of resistancereputable_journalism
Theo Baker · Stanford Daily · 2023-12-31
[16]
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Diseasepeer_reviewed
Gary P Morris, Ian A Clark, Bryce Vissel · Acta Neuropathol Commun · 2014-09-18
[17]
The controversy around anti-amyloid antibodies for treating Alzheimer’s diseasepeer_reviewed
Philip Hunter · EMBO Rep · 2024-10-23
[18]
What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?peer_reviewed
Orestes Vicente Forlenza, Breno José Alencar Pires Barbosa · Dement Neuropsychol · 2025-02-17
[19]
Definition of MIASMAreputable_journalism
Merriam-Webster · Merriam-Webster.com Dictionary · 2026-03-15
[20]
Dietary Goals for the United States, Second Editionprimary_source
Staff of the Select Committee on Nutrition and Human Needs · U.S. Government Printing Office · 1977-12
[21]
Dietary Goals for the United Statesprimary_source
Select Committee on Nutrition and Human Needs, United States Senate Staff · U.S. Government Printing Office · 1977-02
[22]
Dietary Recommendations and How They Have Changed Over Timeprimary_source
Carole Davis and Etta Saltos · USDA Economic Research Service, Agriculture Information Bulletin No. 750 · 1994
[23]
Ancel Keysprimary_source
Blackburn-Keys Collection, University of Minnesota
[24]
The Facts on Fats: 50 Years of American Heart Association Dietary Fats Recommendationsprimary_source
American Heart Association · American Heart Association · 2015-06
[25]
Dietary Goals for the United Statesprimary_source
Staff of the Select Committee on Nutrition and Human Needs · United States Senate · 1977-02
[26]
In 2024, the amyloid-cascade-hypothesis still remains a working hypothesispeer_reviewed
Frontiers in Aging Neuroscience · 2024-01-01
[27]
Microglia modulate Ab-dependent astrocyte reactivity in Alzheimer's diseasepeer_reviewed
Nature Neuroscience · 2025-01-01
[28]
Autophagy in Alzheimer disease pathogenesis and its therapeutic valuespeer_reviewed
Taylor & Francis Online · 2025-01-01
[29]
Trump Or No, Science Badly Needs To Look Inward And Heal Itselfreputable_journalism
Jesse Singal · Jesse Singal Substack · 2025-02-10
[30]
This Is A Low Bar For Alzheimer’s Researchers To Trip Overopinion
Jesse Singal · Jesse Singal Substack · 2023-07-21

Related False Assumptions

Structural Racism Causes Health InequitiesAcademia Economy Medicine Nutrition Policy Public Health
Universal Health Standards Fit All RacesAcademia Medicine Public Health Science Science Policy
Affirmative Action Causes No Reverse DiscriminationAcademia Economy Public Health Science Policy
Gender Care Ethical for Dysphoric KidsAcademia Medicine Public Health Science
Gender is a Social ConstructAcademia Medicine Public Health Science Policy

ID: FA-20260210-01beee13 · Created: 2026-02-10T21:50:00.843549 · Schema v3